Trials / Completed
CompletedNCT00452413
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I: A study to see what doses of Enzastaurin and Erlotinib are best tolerated by participants with solid tumor cancer. Phase II: A study to see how long participants with non-small cell lung cancer (NSCLC) treated with Enzastaurin and Erlotinib live.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | enzastaurin | Administered orally |
| DRUG | erlotinib | Administered orally |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-07-01
- Completion
- 2013-11-01
- First posted
- 2007-03-27
- Last updated
- 2021-05-13
- Results posted
- 2021-05-13
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00452413. Inclusion in this directory is not an endorsement.